Pretreatment Lymphocyte Count Predicts Benefit From Concurrent Chemotherapy With Radiotherapy in Oropharyngeal Cancer.
James M PriceHitesh B MistryGuy BettsEleanor J CheadleLynne DixonKate GarcezTimothy M IllidgeZsuzsanna Iyizoba-EbozueLip Wai LeeAndrew McPartlinRobin J D PrestwichSavvas PapageorgiouDylan J PritchardAndrew SykesCatharine M L WestDavid J ThomsonPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
For OPSCC, the pretreatment ALC is prognostic for OS and also predicts benefit from the addition of cisplatin chemotherapy to radiotherapy. These findings require prospective evaluation, and could inform the selection of good prognosis patients for a de-escalation trial.
Keyphrases
- locally advanced
- rectal cancer
- end stage renal disease
- early stage
- radiation therapy
- squamous cell carcinoma
- ejection fraction
- newly diagnosed
- chronic kidney disease
- radiation induced
- prognostic factors
- peritoneal dialysis
- papillary thyroid
- randomized controlled trial
- open label
- young adults
- phase ii
- squamous cell
- childhood cancer